Early-stage medical technology
Building an evidence-led platform for repeatable oncology imaging research
AquaBIT combines a clinically relevant problem, a differentiated water-assisted acquisition concept and a staged technical-validation pathway. The opportunity is significant—but establishing a new imaging modality requires disciplined scientific, regulatory and capital execution.
Current status: AquaBIT is preclinical and investigational. Technical feasibility, clinical performance, regulatory approval, reimbursement and commercial adoption have not yet been established.
The investment thesis
Persistent clinical need
Longitudinal oncology care requires repeated assessment, while established modalities face different constraints in capacity, cost, tracers, contrast or radiation.
Differentiated acquisition
A conductive-water environment may enable stable, distributed measurements that are difficult to obtain from conventional surface-electrode systems.
Data compounding
Paired electrical, anatomical and outcome datasets could support increasingly capable physics-informed reconstruction and application-specific biomarkers.
Value-creation milestones
- Detectability: demonstrate target recovery across predefined contrast, depth and volume thresholds in simulation.
- Physical validation: recover blinded targets in tissue-equivalent phantoms with acceptable repeatability.
- Integrated prototype: combine chamber, electrode array, electronics, calibration, safety and reconstruction.
- Human feasibility: demonstrate safe, reproducible acquisition under an approved research protocol.
- Clinical signal: establish prospective agreement or incremental value against appropriate reference standards.
Development capital priorities
Physics and modelling
Finite-element models, inverse methods, uncertainty estimation and study-design simulation.
Prototype engineering
Electrode arrays, acquisition electronics, chamber engineering, calibration and human factors.
Evidence generation
Phantom validation, quality systems, regulatory planning and prospective clinical feasibility.
The risks are real—and measurable
The central risks include insufficient spatial sensitivity, unstable inverse reconstruction, physiological confounding, prototype complexity, clinical workflow burden and failure to add value beyond established imaging. The programme is structured to confront these risks early through explicit go/no-go criteria.
Partner at the evidence-building stage
We welcome discussions with investors and strategic partners experienced in medical imaging, oncology diagnostics, regulated hardware, clinical AI and translational research.
TECHNICAL DUE DILIGENCE
Review the AquaBIT scientific and development thesis
The white paper explains the proposed architecture, oncology-first hypothesis, evidence boundaries, principal technical risks and the milestones required before clinical utility can be claimed.
AquaBIT Medical 